Upcoming clinical trial results could push these stocks through the roof before 2024 is finished.It's hard to overstate just how successful weight-management treatments have been over the past couple of years. Sales of semaglutide, the drug that Novo Nordisk (NVO -2.99%) markets as Ozempic and Rybelsus for diabetes, and as Wegovy for weight management, have soared to an annualized $27.9 billion.Semaglutide first earned approval from the Food and Drug Administration (FDA) back in 2017. A much younger treatme ...

Amgen (AMGN) closed at $335.61 in the latest trading session, marking a -0.52% move from the prior day. This change lagged the S&P 500's daily gain of 0.28%. Elsewhere, the Dow gained 0.15%, while the tech-heavy Nasdaq added 0.15%.Shares of the world's largest biotech drugmaker witnessed a gain of 2.61% over the previous month, beating the performance of the Medical sector with its gain of 0.38% and the S&P 500's gain of 2%.Market participants will be closely following the financial results of Amgen in its ...

These two stocks could be rivals in the intense GLP-1 space in the future.Investing into companies involved with new weight loss medications can be overwhelming. There is a lot of competition in the space given the potential for the anti-obesity market to grow to a size of $100 billion or more, as per estimates from Goldman Sachs.The challenge becomes the following: Do you invest in an established healthcare company that is expanding into this new category of glucagon-like peptide-1 (GLP-1) medications, or ...

Company Performance - Amgen's stock closed at $332.80, reflecting a -0.73% change from the previous day's closing price, underperforming the S&P 500 which gained 0.03% [1] - Over the past month, Amgen's shares increased by 2.22%, while the Medical sector rose by 2.67% and the S&P 500 by 1.54% [1] - The upcoming earnings report is anticipated to show an EPS of $5.13, a 3.43% increase year-over-year, and revenue of $8.51 billion, indicating a 23.24% increase compared to the same quarter last year [1] Annual Estimates - For the annual period, earnings are projected at $19.49 per share and revenue at $33.21 billion, representing increases of +4.5% and +17.82% respectively from the previous year [2] Analyst Estimates and Valuation - Recent changes in analyst estimates for Amgen indicate a dynamic business outlook, with positive revisions suggesting optimism [2] - Amgen currently holds a Zacks Rank of 3 (Hold), with a consensus EPS projection that has decreased by 0.06% in the last 30 days [3] - The company is trading at a Forward P/E ratio of 17.2, which is lower than the industry average of 23.02, and has a PEG ratio of 2.98 compared to the industry average of 2.28 [3] Industry Context - The Medical - Biomedical and Genetics industry, to which Amgen belongs, has a Zacks Industry Rank of 79, placing it in the top 32% of over 250 industries [3] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [4]

Results Illustrate Depth and Diversity of Amgen's Targeted Therapies Across Tumor TypesTHOUSAND OAKS, Calif., Sept. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation of new data across its broad oncology pipeline and portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, taking place Sept. 13-17 in Barcelona. The abstracts showcase data from Amgen-sponsored and investigator-sponsored studies for colorectal, lung, prostate and gastric cancers using molecular ...

Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market.If you want to invest in the fast-growing weight loss industry, going with stocks such as Eli Lilly or Novo Nordisk can seem like a great idea. They have leading weight loss products and possess some promising long-term growth opportunities. But they are already among the most valuable healthcare stocks in the world (their valuations are in excess of $ ...

Hispanolistic/E+ via Getty Images Investment Overview — Tango's Share Price Volatility Based On Competitor's Progress When I last covered Tango Therapeutics, Inc. (NASDAQ:TNGX) for Seeking Alpha, in January of this year, I gave the stock a “Buy” rating. I highlighted the fact that the Boston, Massachusetts-based biotech is one of only five companies to date — the others are Bristol Myers Squibb (BMY) (via its ~$5.8bn acquisition of Mirati Therapeutics), Amgen (AMGN), AstraZeneca (AZN), Johnson & Johnson ...

Central Press/Hulton Archive via Getty Images Written by Sam Kovacs Introduction Buy Low, Sell High, Get Paid To Wait. This is our investment philosophy. I make a point of repeating it as often as I can because it is so simple and elegant, that most investors overlook it. Einstein famously said that everything should be made as simple as possible, but not simpler. Well, this is as simple as it gets for investing. Of course, it brings up quite a few questions: what's low? What's high? Why get paid to wai ...

Amgen Inc. (NASDAQ:AMGN) Wells Fargo 2024 Healthcare Conference Call September 5, 2024 9:30 AM ET Company Participants Justin Claeys - Vice President of Investor Relations Jay Bradner - Executive Vice President, Research and Development & Chief Scientific Officer Peter Griffith - Executive Vice President & Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Mohit Bansal Great. Thank you very much for the third session of the day. My name is Mohit Bansal. I am one of the biopharma ...

A month has gone by since the last earnings report for Amgen (AMGN) . Shares have added about 5.8% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Amgen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Q2 Earnings & Sales BeatAmgen’s second-quarter results were s ...